SE9902989D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- SE9902989D0 SE9902989D0 SE9902989A SE9902989A SE9902989D0 SE 9902989 D0 SE9902989 D0 SE 9902989D0 SE 9902989 A SE9902989 A SE 9902989A SE 9902989 A SE9902989 A SE 9902989A SE 9902989 D0 SE9902989 D0 SE 9902989D0
- Authority
- SE
- Sweden
- Prior art keywords
- hmw
- maa
- cells
- epitope
- displayed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 241000282567 Macaca fascicularis Species 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000005260 human cell Anatomy 0.000 abstract 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 abstract 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9902989A SE9902989D0 (sv) | 1999-08-24 | 1999-08-24 | Novel compounds |
CA002381099A CA2381099A1 (en) | 1999-08-24 | 2000-08-22 | Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody |
NZ517132A NZ517132A (en) | 1999-08-24 | 2000-08-22 | Melanoma associated antigen (HMW-MAA) defined by a monoclonal antibody |
EP00957184A EP1206702A1 (en) | 1999-08-24 | 2000-08-22 | Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody |
PCT/SE2000/001597 WO2001014884A1 (en) | 1999-08-24 | 2000-08-22 | Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody |
AU68837/00A AU762240B2 (en) | 1999-08-24 | 2000-08-22 | Melanoma associated antigen (HMW-MAA) defined by a monoclonal antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9902989A SE9902989D0 (sv) | 1999-08-24 | 1999-08-24 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9902989D0 true SE9902989D0 (sv) | 1999-08-24 |
Family
ID=20416736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9902989A SE9902989D0 (sv) | 1999-08-24 | 1999-08-24 | Novel compounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1206702A1 (xx) |
AU (1) | AU762240B2 (xx) |
CA (1) | CA2381099A1 (xx) |
NZ (1) | NZ517132A (xx) |
SE (1) | SE9902989D0 (xx) |
WO (1) | WO2001014884A1 (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10328121A1 (de) * | 2003-06-23 | 2005-02-03 | Biolife Science Forschungs- und Entwicklungs-GbmH | Passive Immuntherapie gegen malignes Melanom |
SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
CN118420712A (zh) * | 2023-02-01 | 2024-08-02 | 上海健信生物医药科技有限公司 | 一种三特异性抗体技术平台及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
SE9700291D0 (sv) * | 1997-01-31 | 1997-01-31 | Pharmacia & Upjohn Ab | Selection method and prodcts resulting therefrom |
-
1999
- 1999-08-24 SE SE9902989A patent/SE9902989D0/xx unknown
-
2000
- 2000-08-22 WO PCT/SE2000/001597 patent/WO2001014884A1/en not_active Application Discontinuation
- 2000-08-22 CA CA002381099A patent/CA2381099A1/en not_active Abandoned
- 2000-08-22 EP EP00957184A patent/EP1206702A1/en not_active Withdrawn
- 2000-08-22 NZ NZ517132A patent/NZ517132A/en unknown
- 2000-08-22 AU AU68837/00A patent/AU762240B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU762240B2 (en) | 2003-06-19 |
CA2381099A1 (en) | 2001-03-01 |
EP1206702A1 (en) | 2002-05-22 |
NZ517132A (en) | 2003-10-31 |
AU6883700A (en) | 2001-03-19 |
WO2001014884A1 (en) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Livingston et al. | Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside | |
IN2012DN00313A (xx) | ||
AU768002B2 (en) | Immunotherapeutic composition and method for the treatment of prostate cancer | |
EP1568373A3 (en) | Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions | |
CA2523032A1 (en) | Vaccines for cancer therapy | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
MXPA05008128A (es) | Peptidos derivados de survivina y uso de los mismos. | |
Fernandez-Tejada et al. | Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol | |
TW200604208A (en) | Antibodies to angiogenesis inhibiting domains of CD148 | |
BR9913446A (pt) | Produtos de aglicona e métodos de uso | |
WO2004016643A3 (en) | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines | |
WO2004012681A3 (en) | Cancer vaccines containing epitopes of oncofetal antigen | |
CN108348618A (zh) | 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途 | |
CA2360382A1 (en) | Use of antibodies for the vaccination against cancer | |
DE69637571D1 (de) | Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen | |
Lin et al. | Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice | |
JP2002534481A5 (xx) | ||
Wen et al. | Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19 | |
Quan Jr et al. | Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. | |
SE9902989D0 (sv) | Novel compounds | |
AU5097393A (en) | Stimulation of an antitumor t-cell response using anti-idiotypic antibodies | |
HUP0400698A2 (hu) | Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA) | |
TR200401267T4 (tr) | Aşı maddesi olarak antikorların yeni kullanımları. | |
Hong et al. | A vaccine for hypertension based on peptide AngI-R: a pilot study | |
DE60313437D1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 |